Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells

Table 1

Characteristics of HDAC inhibitors in clinical trials.

Chemistry	Compounds	HDAC Targets	Clinical trials	Ref
Hydroxymates	SAHA (vorinostat)	Classes I, II, and IV	Phase III*	[6]
	PXD101 (belinostat)	Classes I, and IIa, HDAC6	Phase II	[7]
	Trichostatin A	Classes I and II	Toxic	[8]
	LAQ824 (dacinostat)	Classes I and II	Phase I	[9]
	PCI24781	Classes I and IIb	Phase I	[10]
	LBH589 (panobinostat)	Classes I and IIa	Phase II	[11]
Cyclic tetrapeptides	FK228 (romidepsin)	HDAC1, 2, 4, 6	Phase II	[12]
Benzamides	MGCD0103 (mocetinostat)	HDAC1, 2, 3, 11	Phase II	[13]
	MS275 (entinostat)	HDAC1, 2, 3, 9	Phase II	[14]
Short-chain fatty acids	Valproic acid	Classes I and IIa	Phase II	[15]
	Butyrate	Classes I and IIa	Phase II	[16]

*Approved (cutaneous T-cell lymphoma).